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BACKGROUND AND PURPOSE 
AMPA receptor positive allosteric modulators represent a potential therapeutic strategy to improve 
cognition in people with schizophrenia. These studies collectively constitute the preclinical 
pharmacology data package used to build conﬁdence in the pharmacology of this molecule and 
enable a clinical trial application. 
EXPERIMENTAL APPROACH 
[N-[(2S)-5-(6-ﬂuoro-3-pyridinyl)-2, 3-dihydro 1H–inden-2-yl]-2-propanesulfonamide] (UoS12258) was 
proﬁled in a number of in vitro and in vivo studies to highlight its suitability as a novel therapeutic 
agent. 
KEY RESULTS 
We demonstrated that UoS12258 is a selective, positive allosteric modulator of the AMPA receptor. 
At rat native hetero-oligomeric AMPA receptors, UoS12258 displayed a minimum effective 
concentration of approximately 10 nM in vitro and enhanced AMPA receptor-mediated synaptic 
transmission at an estimated free brain concentration of approximately 15 nM in vivo. UoS12258 
reversed a delay-induced deﬁcit in novel object recognition in rats after both acute and sub-chronic 
dosing. Sub-chronic dosing reduced the minimum effectivedosefrom0.3 to0.03mg·kg1. UoS12258 
was also effective at improving performance in two other cognition models, passive avoidance in 
scopolamine-impaired rats and water maze learning and retention in aged rats. In side-effect 
proﬁling studies, UoS12258 did not produce signiﬁcant changes in the maximal electroshock 
threshold test at doses below 10 mg·kg฀1. 
CONCLUSION AND IMPLICATIONS 
We conclude that UoS12258 is a potent and selective AMPA receptor modulator exhibiting cognition 
enhancing properties in We conclude that UoS12258 is a potent and selective AMPA receptor 
modulator exhibiting cognition enhancing properties in several rat behavioural models superior to 
other molecules that have previously entered clinical evaluation. 
Abbreviations 
MEST, maximal electroshock seizure threshold test; NOR, novel object recognition 
 
 Introduction 
Many lines of evidence support the premise that enhancing AMPA receptor function should be a 
viable route to treating a variety of disorders that are underpinned by a hypoglutamatergic state, 
such as schizophrenia (Ozawa, 1998, Goff and Coyle, 2001, Sanacora et al., 2008, Zarate and Manji, 
2008). The AMPA receptor itself is a family of tetrameric ionotropic receptors arising from four 
genes that encode four distinct subunits, named GluA1–4, or previously GluR1–4/A-D (Collingridge 
et al., 2009). This diversity of subunits gives rise to heterogeneity of AMPA receptor composition in 
native brain states (Beneyto 2004), further complicated by both the presence of splice variants and 
post-translational editing (Sommer et al., 1990; Seeburg et al., 2001). Two main sub-populations 
arise from the editing of a Ca2+-permeable glutamine residue in the re-entrant M2 loop of the GluA2 
subunit to a Ca2+-impermeable arginine, which renders the edited receptors permeable to just Na+ 
and K+ (Gouaux, 2004). Other than this re-entrant M2 loop, each subunit also comprises three 
transmembrane domains (M1, 3 and 4), an intra-cellular C-terminal domain, key for regulation of 
trafﬁcking, as well as an extensive extracellular N-terminal domain containing both the glutamate-
binding site domain (commonly referred to as the ligand-binding or agonist-binding domain) and an 
N-terminal domain (Traynelis et al., 2010). Functionally active AMPA receptors can be formed from 
any combination of the GluA subunits, although different combinations of different subunits display 
different biophysical and kinetic properties as well as distinct regional distributions and trafﬁcking 
potential (Herguedas et al., 2016). Speciﬁcally for distribution, GluA1, GluA2 and GluA3 subunits are 
found at high levels in the hippocampus, basal ganglia, amygdala, lateral septum and cerebellum in 
rat and macaque, whereas GluA4 is most highly expressed in the cerebellum (Boulter et al., 1990, 
Keinänen et al., 1990, Beneyto and Meador-Woodruff, 2004). Glutamate is the major excitatory 
neurotransmitter, and AMPA receptors are responsible for mediating the majority of fast, excitatory 
synaptic transmission, and as such, offer a great opportunity for modulation for therapeutic beneﬁt. 
Repetitive AMPA receptor stimulation leads to activation of another group of ionotropic glutamate 
receptors, NMDA receptors, by voltage-mediated release of magnesium ion block. This enables 
greater inﬂux of calcium ions into the post synaptic neuron, and onward synaptic transmission and 
processes required for memory deposition and learning, which are further strengthened by 
increased trafﬁcking of AMPA receptors to the membrane (Lynch, 2002). 
Glutamate receptors and schizophrenia 
The considerable body of data linking glutamate receptors to schizophrenia comprises both 
empirical observations and genetic associations. Studies in schizophrenic patients have identiﬁed 
various supporting lines of data, including reduced glutamate concentrations in the CSF (Kim et al., 
1980), reduced hippocampal glutamate from post mortem studies (Harrison, 2000), reduced 
glutamate neurotransmission, reduced carboxypeptidase II (Tsai et al., 1995) and increased N-acetyl 
aspartyl glutamate (endogenous iGlu receptor antagonist) (Jessen et al., 2013). Additionally, 
evidence from immunocyto chemical studies on different brain regions of patients as well as analysis 
of mRNA transcript level changes in hippocampal regions of schizophrenia brains indicates 
reductions in AMPA receptor levels in prefrontal and temporal cortical and thalamic regions that are 
associated with the performance of cognitive tasks (Akbarian et al., 1995, Wright and Vissel, 2012). 
Wider evidence comes from the NMDA receptor, for which it is clear that administration of an 
NMDA receptor blocker, such as phencyclidine or ketamine, is able to both amplify the symptoms of 
schizophrenia in schizophrenic patients (Lahti et al., 1995), and also induce a ‘schizophrenia-like’ 
state including psychosis and disrupted cognition in healthy volunteers (Lahti et al., 2001). These 
data are more compelling for NMDA receptor blocking agents than for other agents, such as 
dopamine-releasers such as the amphetamines (Le Pen et al., 2003). 
AMPA receptor positive modulators 
Given the evidence associating reduced AMPA receptor-mediated neurotransmission with various 
disease states, it is not surprising that considerable effort has been expended in trying to identify 
ways to increase glutamatergic transmission. Direct activation approaches suffer from the loss of 
spatial and temporal control of activation of endogenous glutamate binding and also will run a 
signiﬁcant safety and tolerability risk of generating undesirably high excitatory signalling levels. To 
overcome both of these liabilities, positive allosteric modulators have been targeted over the recent 
decades, such that the glutamate signalling will be enhanced if, and only if, both glutamate and 
positive modulator are bound at the receptor. A range of molecules has been reported, from various 
groups, which have been studied in different preclinical species as well as clinically. These molecules 
have generated considerable in vitro data to support their mechanisms of action, and in particular, 
have been shown to be selective for the AMPA receptor subtype of glutamate receptor over the 
other iGlu and mGlu receptor sub-types (unlike the majority of orthosteric-site binding ligands). In 
addition to effects directly at the receptor, these molecules have demonstrated potentiation in 
native tissue and hippocampal slice preparations, particularly generating facilitation of polysynaptic 
responses (Arai et al., 1996, Lynch, 2002), long-term potentiation, increased BDNF levels and activity 
in a wide range of animal models of learning and memory (Woolley et al., 2009). Speciﬁcally for 
models of cognition, molecules have demonstrated improved performance in olfactory 
discrimination, radial arm maze (Staubli et al., 1994), conditioned fear (Rogan et al., 1997), water 
maze performance (Zivkovic et al., 1995; Quirk and Nisenbaum, 2001), delayed non match to sample 
(Hampson et al., 1998), novel object recognition (NOR) (Lebrun et al., 2000) and passive avoidance 
(PA) (Lebrun et al., 2000, Quirk and Nisenbaum, 2001) in rodents, and have also demonstrated 
encouraging results in non-human primates (Thompson et al., 1995, Buccafusco et al., 2004, Porrino 
et al., 2005). In addition to understanding the behavioural pharmacology, the knowledge of the 
overall structure of the receptor offers the opportunity to exploit structure-based design 
opportunities against the extracellular binding domains (Baranovic et al., 2016). 
AMPA receptor positive modulators – clinical studies 
Although there have been many reports of AMPA receptor positive allosteric modulators in 
preclinical studies, relatively few have been progressed beyond Phase I into patient studies. The 
initial clinical evaluation was driven by the set of CX molecules originating from the University of 
California, subsequently as Cortex, from the pioneering work of Gary Lynch. These molecules initially 
demonstrated effects in healthy young (Ingvar et al., 1997) and aged volunteers (Lynch et al., 1997), 
as well as in schizophrenic patients stabilized on the atypical antipsychotic drug clozapine (Goff et 
al., 2001), but were subsequently ineffective in a later study (Goff et al., 2008). Studies with later 
compounds have generated effects in attention deﬁcit hyperactivity disorder (ADHD) patients (2006, 
Weisler, 2007). The second major class of the phenethylamine sulphonamides produced two clinical 
stage molecules from Lilly, one of which was reported as negative in a Phase II study of cognition in 
Alzheimer’s disease, as well as molecules from GlaxoSmithKline (Ward et al., 2010, 2011) and Pﬁzer 
(Shaffer et al., 2015). 
Methods 
Compound 
The chemical structure of UoS12258 is shown in Figure 1. The preparation and preliminary 
characterization of UoS12258 has been described previously (Ward et al., 2010). 
 
Figure 1 
Concentration–response curve and chemical structure for UoS12258 showing its potentiation of 
glutamate-induced rises in intracellular calcium in HEK293 cells stably expressing the hGluA2i 
homomeric AMPA receptor, pEC50 = 5.57. Responses are normalized to 150 μM cyclothiazide. Mean 
± SEM, n = 6 independent experiments. 
Intracellular Ca2+ influx assay 
AMPA receptors: HEK293 sticky cells (293 TAg/hsr-A pCIP4) were grown in a DMEM/F-12 
supplemented with 10% FBS, 2 mM glutamine and 1.5 ug·mL1 puromycin in a 5% CO2 humidiﬁed 
atmosphere at 37°C. Transient transfection was performed according to the lipofectamine 2000 
method. Brieﬂy, a sub-conﬂuent T-175 cm2 ﬂask was washed with PBS to remove serum and 20 mL 
of optimem were added. Separately, in 10 mL optimem, 100 μg DNA were pre-incubated with 300 μL 
of lipofectamine for 20 min at room temperature and then added to the ﬂask. After 4 h of incubation 
at 37°C, 5% CO2, cells were detached with versene and resuspended in the post transfection 
medium (DMEM supplemented with 10% of dialysed FBS). The conﬂuent monolayer for the 
functional assay was obtained by seeding 7500 cells per well, 2 days before the experiment in 384-
wells, poly-D-lysine coated, black with clear bottom plates (Greiner). 
The following homomeric AMPA receptor subtypes were studied: human GluA1 ﬂip isoform 
(hGluA1i), hGluA3i and hGluA4i and rat GluA2i using DNAs (all Q-unedited in TM2 region to allow 
Ca2+ permeability) hGRIA1i, 3i and 4i, and rGRIA2i. Human GluA2i was studied using the HEK293-
hGR1A2i Q-unedited RC17 cell line that was established in-house. 
NMDA receptors: HEK293 sticky cells, grown at 80–95%conﬂuency in 175 cm2 T-ﬂask, were 
transduced by addition of 5% NR1A-BacMam/25% NR2B-BacMam mixture in 15 mL of medium 
containing DMEM/F-12, 10% dialysed FCS, 0.3 mM MgCl2 and 500 μM ketamine hydrochloride (non-
competitive NMDA receptor antagonist). Cells were incubated with the transduction mixture at 37°C 
in 5% CO2 for 24 h. Then, BacMam was washed away with PBS, and cells were plated onto poly-D-
lysine coated black/clear plates at a density of 20 000 cells per well, always in presence of 500 μM 
ketamine hydrochloride. After an additional 24 h, cells were tested in the ﬂuorescent imaging plated 
reader (FLIPR) assay. 
Kainate receptors: Transient transfection was performed according to the lipofectamine 2000 
method. Brieﬂy, a sub-conﬂuent T-175 cm2 ﬂask was washed with PBS to remove serum and 20 mL 
of optimem were addded. Separately, in 10 mL optimem, 60 μg pcDNA3.2-human GRIK1 
(Q/unedited) were pre-incubated with 300 μL of lipofectamine for 20 min at room temperature and 
then added to the ﬂask. After 4 h incubation at 37°C, 5% CO2, cells were detached with versene and 
re-suspended in the post transfection medium (DMEM supplemented with 10% of dialysed FBS). The 
conﬂuent mono-layer for the functional assay was obtained by seeding 7500 cells per well 1 day 
before the experiment in 384-wells, poly-D-lysine coated, black with clear bottom plates. 
Intracellular calcium levels through AMPA receptors were measured. Buffer comprised (mM): 20 
HEPES, 145 NaCl, 5 KCl, 1 MgCl2,2CaCl2,5.5glucose,pH7.3 with NaOH.On the day of the experiment, 
cell plates were washed three times with the assay buffer using the EMBLA instrument (Skatron), 
and 20 μL of buffer was left in each well. Then 20 μL of Fluo-4AM (Molecular Probes) buffer was 
added to each well to give a ﬁnal concentration of 2 μM, and cells were then incubated at room 
temperature for 60 min in the dark. After the loading incubation, cell plates were washed three 
times to remove unloaded Fluo-4 and 30 μL of buffer was left in each well. Then cell plates were 
placed into the ﬂuorescent imaging plated reader (FLIPR) instrument with 1 W laser power, 10% gain 
and 0.4 s exposure, and a dual addition protocol of 10 min ﬂuorescence measurement was used. 
Com-pounds were collected in 384-well plates at a concentration of 10 mM. A serial dilution (1:3) 
was performed using a Beckman FX. A copy of the serial dilution plates was prepared and diluted 
with buffer immediately before the experiment. The ﬁrst 10 μL addition into a well was from a buffer 
pre-diluted compound plate, and it was followed by 10 min incubation. AMPA positive modulators 
did not give rise to detectable calcium increases when applied in the absence of glutamate. Then for 
the second 10 μL addition, glutamate was applied to give a ﬁnal concentration of 100 μM. Glutamate 
caused a dramatic increase in FLIPR counts when a positive modulator was pre-applied. 
Cyclothiazide (Sigma Aldrich) 150 μM, a known AMPA receptor positive modulator, wasusedasa 
positive control. 
Intracellular calcium measurements through NMDA receptors were obtained in a similar manner to 
that described for AMPA receptors except for the addition of 500 μMketa-mine hydrochloride during 
labelling with FLUO-4. The method used to obtain calcium inﬂux measurements through kainate 
receptors was also similar to that described for AMPA receptors except for the addition of 
concanavalin A (Sigma Aldrich) 0.125 mg·mL฀1, which reduced the level of receptor desensitization. 
Assay quality was determined by calculating the Z0 value: high (150 μM cyclothiazide and 100 μM 
glutamate) and low controls (only 100 μM glutamate) were always present within each 384-well 
plate. FLIPR kinetics data were transformed to a single endpoint using the peak high of the response. 
Values were then normalized to the speciﬁc%increase from  
the 100 μM glutamate effect (0%) to the maximal cyclothiazide positive modulator effect (150 μM) 
in the presence of the 100 μM glutamate stimulation (100%). In general, data from plates were only 
accepted if Z0 > 0.3 and two out of three pharmacological standards had values that were within 3× 
the SD of historical values. The pEC50 for UoS12258 was calculated using a non-linear, four 
parameter logistic curve ﬁtting programme. 
Recombinant receptor electrophysiology 
AMPA receptors: HEK293-hGluA2i unedited RC17 cells were grown in a DMEM medium 
supplemented with 10% FBS, 2 mM glutamine, 10% non-essential amino acids, 
1%penicillin/streptomycin and 500 μg·mL฀1 geneticin (G418) in a 5% CO2 humidiﬁed atmosphere at 
37°C. Cells were plated on glass treated with poly-D-lysine (BD BioCoat cover-slips, BD Biosciences 
Cat.No. 354086) at a density of 50 000–75 000 cells·mL฀1 (2 mL of cell suspension were applied to 
35 × 10 mm petri dish containing the glass cover-slips),keptat30°Cand used, respectively, 1 and 2 
days after plating. Experiments were carried out at room temperature. 
NMDA receptors: HEK293-MSRII cells (passages 19–23) were seeded onto 12 mm poly-D-lysine 
coated coverslips (100 000 cells per 35 mm petri dish holding three coverslips), and the cells were 
transfected 24 h after being seeded. The following DNAs: hNR1A (0.55 μg), hNR2B (2.8 μg) and 
pCMS-EGFP (0.8 μg) were added to the petri dish in the presence of optimem 1 (0.25 mL; Invitrogen) 
and lipofectamine 2000 (9 μL) and incubated for4hat37°Cinanatmosphereof5%CO2. After the 
transfection medium had been rinsed off, the cells were maintained in culture medium containing 
0.3 mM MgSO4 plus 200 μM D-2-amino-5-phosphonovaleric acid (D-AP5; NMDA receptor 
antagonist), at 30°C in an atmosphere of 5 or 10% CO2 for 24 h before the electro physiological 
recordings were obtained. 
The external recording solution comprised (in mM), 140 NaCl, 2 KCl, 1 MgCl2,2CaCl2,10glucose,and 
12HEPES, pH 7.35 (with NaOH). The intracellular solution comprised (in mM) 150 CsCl, 10 EGTA, and 
10 HEPES, pH 7.3 (with CsOH). For perforated patch-clamp recordings, intracellular solution 
containing 240 μg·mL฀1 amphotericin B was used to backﬁll the pipette while intracellular solution 
alone was used to ﬁll the tip. Glutamate (Sigma Aldrich) was dissolved in H2O to generate a 1 M 
stock solution. Cyclothiazide (Sigma Aldrich) was dissolved in DMSO to generate a 100 mM stock 
solution. 
Whole-cell currents were recorded from cells using the perforated patch-clamp technique (Hamill et 
al., 1981; Sherman-Gold, 1993), using the EPC9 or EPC10 patch-clamp system and the Pulse 
programme (HEKA). Patch pipettes were pulled from thin-wall borosilicate glass capillary (1.5 mm 
outer diameter) using a P-97 pipette puller (Sutter Instruments) and had resistances of 2–5MΩ. Cells 
were discarded unless the seal formation permitted low resistance access within 10 min (series 
resistance ≤20 MΩ) due to the amphotericin B. Results were not used when the access resistance 
changed signiﬁcantly during the experiment. Ex-change of solution around the cell was achieved by 
holding thecellinfrontofoneof16–48 channels with a constant solution ﬂow and quickly (10–50 ms) 
moving the chip to place an adjacent channel in front of the cell (Dynaﬂow). 
The cell was clamped at ฀60 mV. Automatic series resistance and capacity compensation were 
applied and checked regularly. The current induced by a 1 s application of the agonist was recorded. 
The agonist application was repeated every 60 s. Control currents elicited by a ﬁxed concentration of 
agonist (3 mM, approximate EC50) were recorded during the experiment in order to monitor any 
variations in charge. For the concentration-response curve, the AUC of the current for the ﬁrst 500 
ms (charge) was measured for the control application of glutamate alone and for glutamate in the 
presence of in-creasing concentrations of the positive modulator (ﬁve different concentrations from 
10 nM up to 100 μM) in the same cell. Cyclothiazide (Sigma Aldrich) 30 μM, a known AMPA receptor 
positive modulator, was used as positive control. 
Concentration-response curves for positive modulator were ﬁtted to the equation of the form: 
 
Y is the response in % normalized to 30 μM cyclothiazide, Top is the extrapolated or asymptote 
maximal % of potentiation, X is the logarithm of concentration. Y starts at 0 and goes to the top with 
a sigmoid shape. Graphs were constructed by averaging the results from all experiments and ﬁtting a 
single curve to the pooled data. 
Native receptor electrophysiology 
Neuronal cultures were prepared from embryonic rat brains harvested following the killing of the 
pregnant female by CO2 inhalation in accordance with GlaxoSmithKline animal welfare guidelines 
and the U.K. Animals (Scientiﬁc Procedures) Act 1986. Animal studies are reported in compliance 
with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015). The dissected hippocampi 
were placed into ice-cold Hank’s balanced salt solution (HBSS) consisting of: pyruvate, 1 mM; 
penicillin, 100 mg·mL฀1; streptomycin, 100 mg·mL฀1; HEPES, 10 mM; NaHCO3,0.035%,Ca2+-and 
Mg2+-free. The tissue was then trypsinized for 30 min at 37°C in trypsin/EDTA diluted (ﬁnal 
concentration 0.05%) in HBSS with sodium pyruvate (Ca2+-and Mg2+-free). Tissue pieces were 
physically dissociated, and neurons were plated onto poly-D-lysine coated coverslips in plating 
medium consisting of: neurobasal medium +1 mM sodium pyruvate; penicillin, 100 mg·mL฀1; 
streptomycin, 100 mg·mL฀1;B27 supplement 1x; L-glutamine, 1 mM. Half of the culture medium was 
replaced twice weekly, and the cells were used for recordings after 5 to 13 days in culture. 
AMPA receptors: Extracellular solution comprised (in mM) NaCl 145, KCl 2.5, HEPES 10, glucose 10, 
CaCl2 1.5, MgCl2 1.2; pH 7.3 with NaOH. Intracellular solution com-prised (in mM) CsF 80, CsCl 80, 
HEPES 10, MgATP 14, DiTRIS creatine phosphate 14, creatine phosphokinase 50 U·mL฀1; pH 7.3 
CsOH. UoS12258 was dissolved in DMSO to generate a 100 mM stock solution. Test solutions were 
diluted to concentrations between 10 nM and 100 μMfromthis stock using extracellular solution 
(maximum ﬁnal DMSO concentration ≤ 0.1%). AMPA (Tocris-Cookson) was dis-solved in H2O to 
generate a 10 mM stock. All experiments were performed at 20–21°C. Whole-cell voltage-clamp re-
cordings from rat cultured hippocampal neurons were made using standard methods (Hamill et al. 
1981). Brieﬂy, using an Axopatch 200B ampliﬁer and pClamp 8.0 software (Axon Instruments) each 
cell was held at ฀70 mV throughout the re-cording and solution exchange was achieved using a fast-
step two-tube perfusion system (Biologic RSC 160). Control AMPA receptor-mediated currents were 
evoked by rapidly moving from normal extracellular solution to an extracellular solution containing 
30 μM AMPA, (approximate EC50 as deter-mined previously) for 2 s then returning to normal 
extracellular solution for 30 s. This cycle of solution changes was repeated continuously throughout 
the baseline recording period. The lowest test concentration of UoS12258 was added to both 
perfusion tubes and the solution change cycle repeated until a stable current was measured. Test 
concentrations were increased sequentially. Inward currents induced by AMPA application were 
complex in that their magnitude and duration depended on three different mechanisms: (i) opening 
of the AMPA receptor channel measured in terms of peak amplitude; (ii) desensitization of AMPA 
receptors measured as the degree of relaxation of the inward current from its initial peak amplitude 
to a reduced steady state plateau level in the continued presence of AMPA; and (iii) deactivation of 
AMPA receptors measured as the rate at which the inward cur-rent decayed back to baseline 
following termination of the AMPA application. 
Peak current amplitude was measured as the difference between baseline current and the maximum 
inward current detected following fast perfusion application of either AMPA alone or AMPA + 
UoS12258. Peak current amplitude, measured at each concentration of UoS12258 in the presence of 
30 μM AMPA, was normalized to the peak current amplitude after application of AMPA alone. 
Desensitization of AMPA receptors is a measure of the reduction from peak in ward current 
amplitude to a steady-state current inﬂux in the continued presence of AMPA. AMPA receptor 
deactivation is the rate at which the inward current returns to baseline after agonist removal and is 
represented by the decay constant, τ, of a mono-exponential curve ﬁtted to the relaxing inward 
current after the AMPA application has stopped. The τ value, measured after each concentration of 
UoS12258 in the presnce of 30 μM AMPA, was normalized to the value of τ after application of 
AMPA alone. Each of these parameters was measured and analysed using Clampﬁt8.0 (AxonInstru-
ments), Excel (Microsoft) and Origin (Microcal). The statistical signiﬁcance of differences in each of 
the measured parameters described above was assessed using Student’s paired t-test (Excel). 
NMDA receptors: Extracellular solution comprised (in mM): NaCl 145, KCl 2.5, HEPES 10, glucose 10, 
CaCl2 1.5, gly-cine (30 μM) – (Mg2+ free to prevent NMDA receptor block). Intracellular solution 
comprised (in mM): K gluconate 140, HEPES 10, NaCl 17, MgATP 4, NaGTP 0.3; pH 7.3 KOH 
Baseline whole cell currents were evoked by rapidly exchanging the perfusing medium from 
extracellular solution to extracellular solution containing 100 μMNMDfor a period of 2 s. In contrast, 
test currents were evoked by rapidly exchanging the perfusing medium from extracellular solution 
containing 100 μM UoS12258 with an extracellular solution containing 100 μM UoS12258 plus 100 
μMNMDA for a period of 2 s. As with baseline currents, each test pulse was separated from the next 
by a 30 s interval. 
Kainate receptors: Extracellular solution comprised (in mM): NaCl 145, KCl 2.5, HEPES 10, glucose 10, 
CaCl2 1.5, MgCl2 1.2; pH 7.3 with NaOH. Intracellular solution comprised (in mM): CsF 80, CsCl 80, 
HEPES 10, MgATP 14, DiTRIS creatine phosphate 14, creatine phosphokinase 50 U·mL฀1; pH 7.3 
CsOH. Baseline whole cell currents were evoked by rapidly exchanging the perfusate medium from 
extracellular solution containing 100 μM SYM2206 (a selective non-competitive AMPA receptor 
antagonist) with an extracellular solution containing 100 μM SYM2206 plus 100 μMkainate for a 
period of 2 s. In contrast, test currents were evoked by rapidly exchanging the perfusate medium 
from extracellular solution containing 100 μM SYM2206 plus 100 μM UoS12258 with an extracellular 
solution containing 100 μM SYM2206 plus 100 μM UoS12258 plus 100 μMkainate fora period of 2 s. 
As with baseline currents, each test pulse was separated from the next by a 30 s interval. 
In vivo electrophysiology 
All animal studies were ethically reviewed and carried out in accordance with Animals (Scientiﬁc 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. 
GlaxoSmithKline safety regulations were adhered to at all times. 
Adult male Lister Hooded rats (Charles River) weighing 243–340 g were housed under a 12 h 
light/dark cycle with food (Harlan Maintenance Diet) and water available ad libitum.   
For electrophysiological recordings, rats were prepared individually. Speciﬁcally, once removed from 
their home cage, they were placed in an induction chamber and anaesthetized with 5% isoﬂurane in 
a 1:1 mix of oxygen and nitrous oxide, which was adjusted to 2.5% isoﬂurane to maintain 
anaesthesia throughout the surgical procedure. Surgery involved cannulating the jugular and 
femoral veins using Portex tubing such that the cannula projected externally from the animal. Each 
rat was then placed in a stereotaxic frame and secured with atraumatic ear bars. Body temperature 
was monitored and maintained at appropriate levels by means of a thermostatically-controlled 
heated blanket and rectal probe. A midline incision was made to expose the dorsal aspect of the 
skull and a burr hole made to allow implantation of a multi-barrelled electrode (Kation Scientiﬁc, 
Hungary) into the CA1 region of the hippocampus (from Bregma: AP ฀4.2 mm, ML 2.4 mm, depth 
1.8–2.2 mm). The multi-barrelled electrode consisted of a carbon ﬁbre recording electrode and three 
glass barrels, two of which were ﬁlled with the following solutions: one barrel contained 2% w.v-1 
methylene blue dissolved in 0.5 M sodium acetate, which acted as the balance for the current 
ejection, and the second barrel contained 5 mM AMPA. A silver ground electrode was also 
positioned under the skin margin. Isoﬂurane levels were lowered to 1.75% before commencement 
of the recordings. Neuronal activity was recorded using a Neurolog NL100 AK head stage connected 
to a NL104A AC preampliﬁer. The signal was ﬁltered (0.5–5 kHz), passed through a Humbug noise 
eliminator and fed into an audio ampliﬁer and a CED 1401 digital analogue interface. Spike 2 
software (CED) was used to record neuronal activity. AMPA was ejected via iontophoresis (currents 
of 4–40 nA) for periods of 40 s, repeated at intervals of 40–60 s. 
UoS12258 was prepared as a nano-milled formulation in 1% w.v-1 HPMC (Pharmacoat 603)/0.1% 
sodium lauryl sulphate (Sigma-Aldrich) in puriﬁed water. The diluent and vehicle was 1% w.v-1 
HPMC/0.1% sodium lauryl sulphate, and all i.v. doses of UoS12258 were administered as 0.05 mL. 
100 g-1. For p.o. dosing, the same batch of UoS12258 that was used for i.v. dosing was administered 
(batch number: VNAA\6768\149\4), vehicle was 1% methylcellulose and dose volume was 2 mL·kg฀1 
in all cases. AMPA (Sigma-Aldrich) was prepared as a 5 mM stock solution in 0.9% saline (pH 8). 
For acute administration, animals were divided into two groups, UoS12258 (n = 4) and saline (n = 3). 
Once a minimum of ﬁve consistent and consecutive responses to AMPA application had been 
achieved, either UoS12258 or saline was injected. In this respect, rats in group one were injected i.v. 
dosed with UoS12258 in a cumulative dosing paradigm consisting of 0.5, 1.0 and 1.5 mg·kg฀1 doses 
delivered at 20 min intervals. A similar procedure was used for the second group of rat sexcept that 
three doses of saline were administered i.v. at 20 min intervals. For sub-chronic administration of 
UoS12258 animals were divided into four groups: vehicle–vehicle (n =5); vehicle–UoS12258 (n =5); 
UoS12258–UoS12258 (n = 5) and UoS12258–vehicle (n =5), where the ﬁrst treatment term indicates 
what the animals were treated with for the 7 day period leading up to the test treatment on day 8; 
this latter treatment being indicated by the second treatment term. The dose of UoS12258 used for 
sub-chronic dosing was 0.03 mg·kg฀1 (p.o.) in a dose volume of 2 mL·kg฀1 and the vehicle was 1% 
methylcellulose (p.o.). All animals were treated at approximately 09 h every day for 7 days. Animals 
receiving UoS12258 on the test day were injected i.v. using a cumulative dosing paradigm 
comprising of 0.1, 0.5 and 1.0 mg·kg฀1 at 20 min intervals, whereas animals receiving vehicle on the 
test day received three doses of saline at 20 min intervals. 
Brains and blood samples (50 μL) were collected at the end of each experiment and frozen at ฀80°C 
in brain and EDTA tubes, respectively, until analysed. UoS12258 content was determined by LC–
MS/Musing QuattrPremie(Micromass) mass spectrometer with positive-ion electrospray ionization. 
Novel object recognitions (NOR) 
Adult male Lister Hooded rats (Charles River) weighing 250–320 g on the day of testing were housed 
in groups of four in the absence of environmental enrichment (sawdust and bedding only) and 
maintained on a 12 h light/dark cycle with lights on at 06:00 h. Food (Harlan Maintenance Diet) and 
water were available ad libitum. For all experiments, rats were habituated to the perspex test arenas 
(42 cm length × 21 cm width × 20 cm height) for 60 min (am) and 3 min (pm) on the day before the 
testing. For experiments 1 and 2, rats were sham dosed with vehicle on four occasions before being 
tested. On the ﬁrst test day, rats were placed in a test arena for a 3 min habituation period and then 
presented with two identical objects (T1, 3 min). Twenty-four hours later rats were placed back in 
the test arena and presented one of the previous (familiar) objects and a novel object (T2, 3 min). 
Ob-jects used were of similar size, black plastic ‘kong’ and cylinder shapes (approximately 6.5 cm 
height × 6 cm width). 
Objects were cleaned with 70% ethanol between animals to remove any odour traces. The novel 
object and novel object side (left or right) was randomized equally across all treatment groups. The 
time spent exploring the objects during T1 and T2 was recorded by an observer blind to the novel 
object. Rats received UoS12258 or vehicle by oral gavage (p.o.). Treatment group sizes were n = 12 
unless stated otherwise. For acute studies, rats were treated 4 h before both T1 and T2 at 0.1, 0.3 
and 1 mg·kg฀1 p.o. For sub-chronic studies, rats were treated once daily (08–10 h) for 7 days 
followed by a single dose 4 h before T1 (day 8) and T2 (day 9) at 0.003, 0.01 and 0.03 mg·kg฀1 p.o. 
In a separate study, male Lister Hooded rats were administered two doses, 24 h apart, of UoS12258 
(0.1, 0.3 and 1mg·kg฀1 p.o.) separated by 24 h to simulate the dosing conditions used in acute 
behavioural studies. Animals were killed 4hafterthe ﬁnal dose following schedule 1 procedures; 
blood and brain samples were taken for analysis. For sub-chronic experiments, animals were killed 
immediately following testing in T2 (n = 3) and blood and brains removed for analysis (as detailed for 
in vivo electrophysiology). 
Water maze 
This paradigm is used to investigate spatial learning and memory where learning and subsequent 
retention of the lo-cation of a hidden platform are measured. Aged rats show an inherent deﬁcit in 
this paradigm such that they do not show an improvement in acquisition of the platform position 
over the course of training and therefore fail to learn where the platform is located, as assessed 
during the probe tasks performed at the end of the training. The effects of sub-chronic 
administration of UoS12258 (0.3, 1, 3 and 10 mg·kg฀1 p.o.) upon age-induced cognitive deﬁcits were 
determined in aged (22 months old) male Wistar rats. UoS12258 was administered once daily in 1% 
methylcellulose for 8 days before the training and then on each training day (3 h prior to each 
session) and also during the recall period, consistent with previous dosing protocols. Plasma samples 
were not taken during this study. During each trial, the latency to ﬁnd the hidden platform (to a 
maximum of 90 s) was recorded. Animals received ﬁve trials per day (inter-trial interval of 300 s) for 
4-days. Recall of platform position was assessed by a probe test at 1, 3and7daysfollowingthe ﬁnal 
training session, in which the platform was removed and animals were allowed to explore the maze 
for 30 s. The time spent in each quadrant was recorded. 
Passive avoidance (PA) 
The PA procedure is based on the ability of rats to associate a speciﬁc context (dark chamber) with 
an aversive conditioned stimulus (0.75 mA, 0.5 s scrambled foot shock). This experiment investigated 
the effects of acute UoS12258 on a scopolamine (0.08 mg·kg฀1 i.p.)-induced deﬁcit in PA in male 
Wistarrats.UoS12258 (0.1,1,3and10mg·kg฀1 p.o.) with the 5-HT6 receptor antagonist, SB-399885 T 
(10 mg·kg฀1 p.o.) used as a positive control. Test drugs were administered in 1% methylcellulose 3 h 
before the onset of training. Scopolamine hydrobromide (0.8 mg.kg฀1 i.p.) was dissolved in saline 
and administered 6 h post training. Plasma samples were not taken during this study. On the training 
day, rats were treated with vehicle or UoS12258 3 h prior to assessment of spontaneous activity in 
the open ﬁeld apparatus. Immediately afterwards, the rats were placed in the light compartment 
and the latency to enter the dark chamber was recorded. Upon entering the dark compartment, rats 
received a foot shock (0.75 mA, 0.5 s) and returned to the light chamber whereupon they were 
returned to their home cage. Recall of this inhibitory stimulus was evaluated 24 h post-training by 
returning the animal to the light chamber and recording the latency to enter the dark chamber up to 
a maximum of 600 s. At no point during the test period was a foot shock given. 
Microdialysis 
Male Lister Hooded rats (250–275 g) were housed in groups of four, kept under a 12 h light/dark 
schedule, lights on at 07:00 h with food and water available ad libitum. 
General anaesthesia was induced using isoﬂurane. Once deep anaesthesia had been obtained, rats 
were administered synulox (antibiotic; s.c.) and rimadyl (analgesic; s.c.), and the rat transferred to a 
stereotaxic frame. The skull was ex-posed and holes drilled relative to the Bregma, four anchor 
screws (1.6×3mmstainless steel cheese head screws, Wood and Hughs), and additional holes drilled 
at 12° to the dura surface for placement of microdialysis guide cannula (CMA 11, CMA, UK) into the 
dorsal hippocampus (AP: + 3.5 mm, ML ฀2.0 mm, and DV – 2.0) and anterior cingulate cortex (AP: + 
2.7 mm, ML ฀1.6 mm, and DV – 2.0 mm) according to Paxinos and Watson (1986). Probe and anchor 
screws are secured in place with dental cement (Poly-F-plus, zinc polycarboz cement, Cladius Ashe), 
and the wound sealed. Postoperative ﬂuids (5 mL saline,2.5 mL per side;s.c.) andanalgesic (Nubain 
0.4 mL·100 g฀1; s.c.) were administered to aid recovery. The rats were monitored until they regained 
their righting reﬂex and received at least 5 days post-operative care. 
Eighteen hours before the start of the dialysis experiment, rats were moved into microdialysis cages 
(285 mm diameter, 355 mm high; manufactured in-house) to allow for overnight acclimatization to 
the dialysis procedure room. On the morning of each experiment, microdialysis probes (CMA 11, 
14/02, Linton Instruments; 2 mm active membrane) were perfused with a buffered artiﬁcial CSF 
(aCSF) solution (comprising in mM: 145 NaCl, 2.7 KCl, 1 MgCl2,1.2CaCl2 and 2 Na2HPO4) at 1 
μL·min฀1 via a dual-channel liquid swivel (Instech 375/D/22QE microdialysis swivel, BAS). 
Microdialysis probes were inserted into the implanted guide cannulae and per-fused with aCSF for 2 
h before sampling began, to allow for equilibration of neurotransmitter levels, following which 
samples were collected every 30 min. Four dialysate samples were collected to generate baseline 
readings before administration of either test compound. UoS12258 was dissolved in 1% 
methylcellulose and sonicated prior to administration. Doses of UoS12258, 0.1, 0.3 and 1 mg·kg฀1, 
orvehicle (1%methylcellulose) were administered in a volume of 2 mL·kg฀1, p.o. Following 
administration of compound, a further 10 dialysate samples were collected until the end of 
sampling. Dialysate samples were analysed for 5-HT, dopamine (DA) and noradrenaline (NA) using 
HPLC with electrochemical detection and ACh using mass spectrometry. At the end of each 
experimental day, animals were returned to their home cage and reused in a randomized cross-over 
design, allowing at least 7 days drug washout before subsequent uses. After the ﬁnal experiment, 
brains were removed and stored in formalin solution for probe placement veriﬁcation. 
All dialysate samples were calculated as a subsequent percentage of the average absolute levels of 
neurotransmitters from the four baseline samples prior to administration of compound. Signiﬁcant 
differences between groups of the same compound were calculated by repeated measures ANOVA 
followed by Fischer’s least signiﬁcance difference post hoc test where appropriate with signiﬁcance 
set at P < 0.05 (Statistica v6.0). 
Maximal electroshock threshold test 
Adult male Sprague Dawley or Lister Hooded rats (Charles River) weighing 95 to 160 g on the day of 
testing were housed in groups of six or less and maintained on a 12 h light/dark cycle with lights on 
at 06:00 h. Food (Harlan Maintenance Diet) and water were available ad libitum. Treatment groups 
of 12 animals were administered UoS12258 at 10, 30 or 100 mg·kg฀1 by p.o. gavage 2 h before 
testing (expt 1) or 30 mg·kg฀1 p.o. 2, 5 or 7 h before testing in Sprague Dawley rats (expt 2) or 1.0, 
3.0, 10 mg·kg฀1 4hbeforetesting in Lister Hooded rats (expt 3). In all experiments, the known pro-
convulsant, picrotoxin (2.0 mg·kg฀1 as a positive control) was administered i.p. 30 min before 
testing. After the animals had been treated, they were returned to their home cages. Testing 
occurred in a separate room and consisted of assessing the induction of a tonic hind limb extensor 
seizure following a 0.1 s shock administered via corneal electrodes according to the ‘up and down’ 
method (Kimball et al., 1957). In all experiments, a separate group of animals (n =3 per dose) was 
treated and blood and brain samples taken at the appropriate pre treatment time for analysis of 
compound levels. The threshold for tonic hind limb extensor seizures was determined using a Hugo 
Sachs Elektronic stimulator, which delivered a constant current of 0.1 s duration, 50 Hz, sine wave 
form, fully adjustable between 1 to 300 mA, via corneal electrodes. The electrodes were brieﬂy 
immersed in saline before application of the electroshock in order to achieve good electrical contact. 
Results 
Functional activity at recombinant human GluA2i homomeric AMPA receptors 
The functional activity of UoS12258 at the hGluA2i homomeric AMPA receptor stably expressed in 
HEK293 cells was assessed using FLIPR/Ca2+ inﬂux methodology. Application of glutamate (100 μM) 
alone did not elicit a signal due to rapid desensitization of the AMPA receptor. However, in the 
presence of UoS12258, application of glutamate consistently increased intracellular Ca2+ levels such 
that an increase in the concentration of UoS12258 produced a progressive potentiation of 
glutamate-induced responses. A non-linear, four-parameter logistic curve-ﬁt of the data generated 
pEC50 and maximum potentiation values (relative to the established AMPA receptor positive 
modulator cyclothiazide, 150 μM) of 5.57±0.07and100.7±3.9%respectively(n =6; Figure 1). When 
applied alone, in the absence of glutamate, UoS12258 did not affect intracellular Ca2+ levels 
indicating that it possessed no intrinsic agonist activity. 
Electrophysiological activity at human recombinant GluA2i homomeric AMPA receptors 
Using this approach, UoS12258 potentiated glutamate-induced whole-cell, AMPA receptor-mediated 
currents producing a maximal response that amounted to 112 ± 32% of the maximal response 
induced by the reference AMPA receptor positive modulator cyclothiazide (30 μM). The pEC50 value 
(5.19 ± 0.02; n = 4, Figure 2) for this positive modulatory effect of UoS12258 was in close agreement 
to that generated using the FLIPR/Ca2+ inﬂux assay described above. 
Functional activity at recombinant human GluA1i, GluA3i, GluA4i and rat GluA2i homomeric AMPA 
receptors 
To demonstrate (i) the broad spectrum positive modulatory activity of UoS12258 across AMPA 
receptors formed from different GluA subunits, and (ii) lack of species-dependent pharmacology, 
FLIPR-based assays were used to assess its activity at human AMPA receptors formed by homomeric 
assembly of GluA1i, 3i or 4i subunits as well as homomeric assembly of rat GluA2i subunits 
transiently transfected into HEK293 cells (Table 1). There was less than a 10-fold difference be-
tween pEC50 values for all hGluAi homomeric AMPA receptors and between rat and human GluA2i 
indicating that UoS12258 possesses little speciﬁcity for individual GluA sub-units or across species 
(Supporting Information Table 1). 
 
Figure 2 
(A) Representative whole cell current traces recorded from a single HEK293 cell expressing hGluA2i 
homomeric AMPA receptors. UoS12258 (1–100 μM, upper concentration limited by solubility) 
produced a concentration-dependent and reversible increase in charge transfer. Positive modulator, 
cyclothiazide (CTZ) 30 μM, also increased charge transfer following application of glutamate (line 7). 
(B) Concentration–response curve for the potentiation of hGluA2i-mediated inward currents by 
UoS12258, pEC50 = 5.19. Responses are normalised to 30 μM cyclothiazide. n = 4 independent 
experiments. 
Potentiation of rat native AMPA receptor-mediated responses 
Repeated (2 s duration, every 30 s) applications of 30 μM AMPA in rat cultured hippocampal 
neurons produced inward currents, the peak amplitude and waveform of which were consistent in 
magnitude between successive applications. Measurements taken reﬂected the three different 
mechanisms which occurred during this period: (i) opening of the AMPA receptor channel measured 
in terms of peak amplitude; (ii) desensitization of AMPA receptors measured as the degree of 
relaxation of the inward current from its initial peak amplitude to a reduced steady state plateau 
level in the continued presence of AMPA; and (iii) deactivation of AMPA receptors measured as the 
rate at which the inward current decayed back to baseline following termination of the AMPA 
application. 
Table 1 
Effect of UoS12258 (10, 30, 100 mg·kg฀1, p.o., 2 h pretreatment) in CD rats in the pro-convulsant 
MEST test 
 
 Figure 3 
Rat native neuronal data. (A) Concentration-response plot for UoS12258-mediated potentiation of 
charge transfer. (B) Concentration-response plot for UoS12258-mediated potentiation of AMPA 
receptor deactivation. (C) Concentration–response plot for the inhibition of AMPA receptor 
desensitization induced by UoS12258. Responses were normalized to 30 μM AMPA control. Lowest 
concentration to cause a signiﬁcant (*P < 0.05) difference. 
 
While UoS12258 alone did not evoke a whole-cell in-ward current at any concentration tested (10 
nM–00 μM), application of 30 μM AMPA in the presence of UoS12258 produced inward currents 
that exhibited larger peak amplitudes, reduced desensitization and slowed deactivation, which all 
contributed to an increase in charge transfer (area under the inward current), relative to control 
responses in the absence of UoS12258. The effect of UoS12258 on each of these electrophysiological 
parameters was clearly concentration-dependent and was ﬁrst evident in the nM concentration 
range. 
Thus, although the pEC50 and maximal potentiation of charge transfer induced by UoS12258 were 
increased by 5.1 and a 4.1 ± 0.97-fold, respectively, 10 nM UoS12258 produced a statistically 
signiﬁcant 1.4-fold increase in charge transfer when compared to AMPA alone ( n =8; P < 0.05, 
Student’s paired t-test, Figure 3A). 
UoS12258 produced a concentration-dependent increase in the rate constant of AMPA receptor 
deactivation (pEC50 5.3) such that at 100 μM the rate of deactivation was 5.9 ± 1.5-fold greater than 
that produced by AMPA application alone. As with charge transfer UoS12258 also potentiated this 
component of the AMPA receptor-mediated response at nM concentrations such that at 10 nM it 
produced a 44 ± 6% decrease in the rate of deactivation (P < 0.05, Student’s paired t-test n 
=7;Figure3B). 
In contrast to the signiﬁcant increases in both charge transfer and rate of deactivation, inhibition of 
AMPA receptor desensitization by UoS12258 was more variable and only statistically signiﬁcant at 
concentrations of 10 μMand above where agreaterthan52±17%reductioninAMPA receptor 
desensitization was observed (n =7,P < 0.05, Student’s paired t-test, Figure 3C). 
Notably, since the minimum effective concentration of UoS12258 on desensitization was 10 μM, the 
previously described potentiation of charge transfer at 10 nM reﬂects UoS12258-mediated 
potentiation due to changes in peak amplitude and deactivation (Supporting Information Table S2). 
Selectivity versus recombinant NMDA and kainate receptors 
In the NMDA receptor FLIPR assay, UoS12258 (tested up to 50 μM, n = 4) did not show any activity 
either as an opener or blocker at human GluN1/2B receptors. Similarly, in the electrophysiology 
experiments, UoS12258 did not potentiate GluN1/2B receptor-mediated activity at either 10 nM, the 
minimum concentration (paired t-test, n =5)or1 μM, 100 times the minimum concentration (paired 
t-test, n =5) shown to potentiate AMPA-mediated currents; although there was a partial inhibition 
(18 ± 1% at 100 μM, P < 0.05, paired t-test, n =5) when tested at100 μM. 
In FLIPR experiments on transiently expressed GluK1 (Q-edited) homomeric kainate receptors, 
UoS12258 (up to 50 μM, n = 3) did not show any activity either as an agonist, antagonist or positive 
modulator. Identical results were obtained using electrophysiological analysis. 
Functional selectivity versus rat native NMDA and kainate receptors 
In separate neurons, repeated applications of either NMDA, in the presence of NMDA receptor co-
agonist glycine, or kainate, in the presence of the selective AMPA receptor antagonist SYM2206, 
generated reproducible inward currents that were mediated by activation of NMDA receptors and 
kainate receptors, respectively, and that were not signiﬁcantly affected by UoS12258 (100 μM) (n = 4 
for both; paired t-test). There were also no signiﬁcant changes in NMDA receptor-mediated charge 
transfer with UoS12258 at either 10 nM, the minimum concentration (paired t-test, n =4)or1μM, 100 
times the concentration (paired t-test, n =4)show no potentiate AMPA-mediated currents. 
Potentiation of AMPA receptor-mediated synaptic responses in vivo 
The effect of UoS12258 was evaluated in vivo in an electro-physiological model where synaptic 
connectivity is intact, speciﬁcally the potentiation of electrically evoked AMPA receptor-mediated 
synaptic potentials were recorded from the dentate gyrus of the anaesthetized rat. Electrical 
stimulaion of the medial perforant pathway evoked a population spike recorded in the hippocampal 
dentate gyrus granule cell layer. UoS12258 (0.1 mg·kg฀1 i.v.) signiﬁcantly increased population spike 
amplitude by18± 3%compared to vehicle (Figure 4, P < 0.05, n =4 ANCOVA, univariate test of 
signiﬁcance. Analysis of brain samples taken immediately after the experiment generated a mean 
UoS12258 concentration of 198 ± 40 ng·g฀1). Brain tissue binding for UoS12258 was measured as 
97.4% resulting in an estimated mean unbound concentration of 5.1 ng·g฀1, which equates to an 
approximate free concentrationof15nM, which is in close agreement with the MEC (10 nM) for 
UoS12258 induced potentiation of AMPA receptor-mediated charge transfer and deactivation in rat 
hippocampal neurons. 
NOR test 
The NOR test is a two-trial recognition memory test of the ability of rats to discriminate between 
novel and familiar objects. NOR can be impaired by inserting a time delay (24 h) between 
presentations of the objects. 
Data are expressed both as total time spent exploring the novel and familiar objects in T2 and as the 
d2 index (proportion of time exploring the novel object in T2). In the ﬁrst study, acute UoS12258 
(0.1, 1, 10 mg·kg฀1) produced a bell-shaped dose-response curve (i.e. improvement in object rec-
ognition at 1 mg·kg฀1 with alossofeffectat10mg·kg฀1). At the higher dose 1 rat out of 12 had a 
seizure and was excluded from the test. Based on an efﬁcacious dose of 1 mg·kg฀1, a follow up 
experiment was conducted to assess a lower dose range (i.e. 0.1–1mg·kg฀1 p.o.). Following acute 
administration, UoS12258 signiﬁcantly increased novel object exploration compared to vehicle-
treated rats at 0.3 (P < 0.05) and 1mg·kg฀1 (P < 0.05, Figure 5A) and the d2 index (P < 0.05, Figure 
5A). In a separate study, mean blood and brain levels of UoS12258 were determined in rats dosed 
under identical conditions (n = 3) and are shown in Supporting Information Table S3. 
Following 7 day sub-chronic dosing plus treatment 4 h be-fore T1 and T2, UoS12258 signiﬁcantly 
increased novel object exploration compared to vehicle treated rats at 0.03 mg·kg฀1 (P < 0.05, 
Figure 5B). The d2 index was signiﬁcantly increased at both 0.01 and 0.03 mg·kg฀1 (P < 0.05, Figure 
5B). The sub-chronic MED was determined as 0.03 mg·kg฀1 based on signiﬁcant changes in both 
measures. Mean blood and brain levels of UoS12258 in rats sampled immediately after testing are 
presented in Supporting Information Table S4 (n =3). A previous sub-chronic NOR study with 
UoS12258 (0.03, 0.1, 0.3 mg·kg฀1) also exhibited a bell-shaped dose–response curve with efﬁcacy at 
0.03 and 0.1 mg·kg฀1 and no effect at 0.3 mg·kg฀1.Thus, wo studies conﬁrm that sub-chronic dosing 
with UoS12258 results in increased potency to facilitate NOR learning, in accordance with data 
reported in the literature for compounds of this class. 
 
Figure 4 
Representative traces recorded from the dentate gyrus of the anaesthetized rat following vehicle 
(left trace) and 0.1 mg·kg฀1 i.v. administration of UoS12258 (right trace). Synaptic traces are an 
average of 10 consecutive responses; the population spike is ringed in blue. 
 
 
 Figure 5 
(A) Effects of UoS12258 on NOR in rats after acute administration (0.1–1mg·kg฀1 p.o., 4 h prior to T1 
and T2); (B) Effects of UoS12258 on NOR in rats after 7 day sub-chronic administration (0.003–0.03 
mg·kg฀1 p.o. dosed daily for 7 days and then 4 h prior to T1 and T2). Statistical analysis was 
performed using ANOVA, followed by planned comparisons (*P < 0.05) to vehicle-treated animals. 
Passive avoidance 
Neither UoS12258 nor SB-399885T (5-HT6 receptor antagonist) had any effect on spontaneous open 
ﬁeld activity (data not shown), suggesting a lack of confounding motor effects. Scopolamine 
impaired passive avoidance (P < 0.05, Figure 6). UoS12258 (10 mg·kg฀1) did not impair performance 
when given alone, and prevented the scopolamine-induced impair-ment in a dose-dependent 
manner (P < 0.05), with signiﬁcant effects observed at 3 and 10 mg·kg฀1 (P < 0.05). The positive 
control SB-399885T also prevented the scopolamine-induced memory deﬁcit (P < 0.05). 
Morris water maze in aged rats 
UoS12258 signiﬁcantly reduced escape latencies following 3 and 10 mg·kg฀1 (Figure 7; F[1180] = 
14.1 and 5.9, P < 0.05 for 3 and 10 mg·kg฀1 vs. vehicle-treated controls). 
UoS12258 signiﬁcantly reduced swim angle, the angle between start position and the position of the 
hidden platform in the water maze, over the four training sessions 
 
Figure 6 
Effects of acute UoS12258 and SB-399885T on scopolamine-induced impairment of a passive 
avoidance response in adult Wistar rats. Data represent mean ± SEM avoidance latency at the 24 h 
recall time. Signiﬁcant difference (*P < 0.05) compared to scopolamine-treated animals (Mann–
Whitney U-test, n = 6 per group). 
(F[1,36] = 19.7 and 5.1; P < 0.05 for 3 and 10 mg·kg฀1 vs. vehicle-treated), suggesting an improved 
search strategy (data not shown). UoS12258 had variable effects upon swim speed, that is, no 
consistent increase in swim speed at doses shown to be efﬁcacious at improving acquisition, which 
therefore does not explain the reduced latency to ﬁnd the hidden platform. 
 
Figure 7 
Effect of sub-chronic UoS12258 on acquisition of a water maze spatial learning task by aged Wistar 
rats. Data represent mean ± SEM escape latency (s) averaged over the ﬁve trials of each training 
session. By session 3 there was a signiﬁcant, P < 0.05, difference between groups administered 
either 3 or 10 mg·kg฀1 compared to vehicle treated animals (n = 6 per group). 
Recall of the hidden platform position was assessed by probe trials carried out 1, 3 and 7 days 
following the ﬁnal training session. UoS12258 (3 mg·kg฀1) improved recall of the task in all three 
probe trials (Figure 7, P < 0.05, Mann–Whitney U-test). UoS12258 (10 mg·kg฀1) signiﬁcantly 
improved recall in the 1 day post-training probe trial only (Figure 8). 
Microdialysis 
UoS12258 signiﬁcantly (F3, 23 = 5.94, P < 0.05) increased extracellular levels of ACh in the anterior 
cingulate cortex at all three doses and induced a signiﬁcant (F3,22 = 5.076, P < 0.05) increase in the 
dorsal hippocampus again at all three doses(Figure9). UoS12258 also induced signiﬁcant (F3,24 = 
4.47, P < 0.05) increases in extracellular dopamine levels at both 0.3 mg·kg฀1 (P < 0.05) and 1 
mg·kg฀1(P < 0.05) (Figure 9). There was no signiﬁcant effect of AMPA positive modulation on 
extracellular levels of 5-HT or NA in any of the brain structures studied. 
 Figure 8 
Effect of sub-chronic UoS12258 on recall of a water maze spatial task by aged rats. Data represent 
mean ± SEM time (s) swimming in the target quadrant of the water maze during probe trials 1, 3 and 
7 days post-training. Signiﬁcant difference (*P < 0.05) compared to vehicle treated animals. 
Side effect profiling using maximal electroshock seizure threshold test (MEST) 
In order to assess the potency of UoS12258 to potentiate induced seizure activity, rats were 
pretreated with the com-pound prior to induction of seizure. Corneal application of an electrical 
current (CC50 approximately 60–70 mA, 0.1 ms duration) in the rat induces tonic and full tonic–
clonic seizures. In separate experiments, UoS12258 was administered 10, 30, 100 mg·kg฀1, p.o., 2 h 
pretreatment; 30 mg·kg฀1, p.o., 2, 5, 7 h pretreatment to SD rats; 1.0, 3.0 10 mg·kg฀1, p.o., 4 h 
pretreatment to LH rats before testing for proconvulsant activity. LH rats were chosen to provide a 
comparison with the NOR potency data. 
In SD rats, UoS12258 signiﬁcantly decreased seizure threshold at30and100mg·kg฀1 by ฀41 (3390 
ng·g฀1 in brain) and ฀58% (4961 ng·g฀1 in brain), respectively, 2 h post dose (Table 1). A subsequent 
DMPK study showed that the concentration was equivalent at 2 and 5 h. Therefore, in a re-peat 
study, UoS12258 (30 mg·kg฀1 p.o.) was tested 2, 5 and 7 h post dose. Seizure threshold compared to 
vehicle (5 h pre-treatment) was reduced at all time points by ฀54, ฀43 and ฀57 (2, 5 and 7 h 
pretreatment respectively). At 2 h 1/13 an-imals and at 7 h 1/15 animals showed spontaneous 
convulsions and were killed just before testing. In LH rats, UoS12258 signiﬁcantly reduced seizure 
threshold by ฀38%at 10 mg·kg฀1 (Supporting Information Table S5). Both rat strains show similar 
brain exposure (2446 ng·g฀1 in LH vs. 2283 ng·g฀1 SD at 10 mg·kg฀1). 
Discussion 
In this article, we present data from experiments that describe the pharmacological properties of 
UoS12258, a novel and selective AMPA receptor positive modulator. Although, as stated earlier, 
many molecules have been investigated pre-clinically and several have progressed into clinical trials, 
there is limited full disclosure of the enabling preclinical data sets – particularly regarding 
behavioural and tolerability data. To address this situation, we disclose the data set generated for 
this molecule, which has progressed into clinical evaluation, including details of the differences 
observed in behavioural studies between acute and repeat dosing and also the clear side effects 
seen at elevated concentrations. In addition to the studies reported below, a wider investigation was 
con-ducted of UoS12258 in additional behavioural pharmacology models, for which the data were 
either inconclusive: reversal of ketamine or amphetamine-induced hyperactivity in rat and reversal 
of quinelorane (D2/3 receptor agonist)-induced hypoactivity in rat, or only effective at high doses: 
mouse forced swim test (10 mg·kg฀1 p.o. administered 240 min prior to test gave efﬁcacy of 
imipramine dosed i.p. 30 min prior to test). Full data for these studies are not included in this 
manuscript due to space restrictions. 
 
Figure 9 
Changes in levels of ACh and dopamine (DA) expressed as % changes from basal (line graphs) and 
total efﬂux (bar chart – calculated as AUC of %changes from basal levels) in the anterior cingulate 
cortex (left panel) and dorsal hippocampus (right panel) following administration of UoS12258 (0.1, 
0.3 and 1.0 mg·kg฀1,p.o). *P < 0.05, signiﬁcant differences compared to vehicle treated animals. 
Characterization using recombinant systems 
We investigated the effect of UoS12258 on intracellular Ca2+ inﬂux using FLIPR-based assays, and 
the results suggest that UoS12258 shows no clear subunit speciﬁcity and should act equipotently at 
heteromeric AMPA receptors with different subunit compositions, which exist in native tissues. Also, 
given that pEC50 values for UoS12258 were similar at rat and human, there appears to be little 
evidence of species selectivity. Using the same recombinant system, HEK293-hGluA2i stable cell line 
with whole-cell voltage clamp electrophysiology, the pEC50 for UoS12258 was again similar to the 
FLIPR values with this AMPA receptor subunit. 
Characterization using native systems 
Although rates of receptor activation and deactivation are comparable across all homomeric AMPA 
receptors and are therefore independent of AMPA receptor GluA subunit complement, 
desensitization kinetics differ depending upon AMPA receptor subunit stoichiometry (see 
Schlesinger et al., 2005). As whole cell currents in neurons sample activation of a heterogeneous 
population of AMPA receptors that will differ from neuron to neuron, it is likely that the observed 
variation in desensitization is due to the heterogeneity of the AMPA receptor populations assessed. 
Activation (charge transfer) and deactivation of AMPA receptors are measures that deﬁne the onset 
and offset of glutamatergic activity and are therefore directly relevant to the propagation of synaptic 
transmission and synaptic plasticity. Receptor desensitization, during which the receptor becomes 
inactive in the continued presence of the ligand, has been more closely associated with excessive or 
pathological glutamatergic activity. In native hippocampal neurons using whole-cell voltage clamp 
electrophysiology, it was possible to measure AMPA receptor-mediated charge transfer and 
deactivation which were potentiated signiﬁcantly by concentrations of UoS12258 as low as 10 nM. It 
is interesting, however, that the pEC50 of UoS12258 on charge transfer, desensitization and 
deactivation of AMPA-mediated currents in native neurons are all in the same range as the pEC50 
values in recombinant systems. There are clearly many physiological differences between 
recombinant and native systems for ex-ample increased levels of phosphorylation, the presence of 
transmembrane AMPA regulatory proteins or increased AMPA receptor expression at the cell 
membrane, which could ex-plain the observed low concentration-mediated potentiation of AMPA 
receptors by UoS12258 in the native system. Perhaps of more interest this concentration is 
comparable to the concentrations measured in the brain immediately after in vivo 
electrophysiological studies, in which UoS12258 increased AMPA receptor-mediated synaptic 
activity. Together these data mutually support the observation that, at equivalent concentrations, 
UoS12258 evoked signiﬁcant potentiation of AMPA receptor-mediated neuronal activity both in vitro 
and in vivo. 
The selectivity of UoS12258 for AMPA subtype glutamate receptors could however be a desirable 
property since activation and/or potentiation of other ionotropic glutamate receptor subtypes (i.e. 
NMDA and kainate) could cause excessive glutamate channel opening, increasing Ca2+ inﬂux and 
lead-ing to excitotoxic damage. To establish its selectivity for the AMPA receptor, the functional 
activity (agonism, antagonism and positive modulation) of UoS12258 was assessed at the human 
heteromeric NMDA receptor GluN1/2B and the hu-man GRIK1 (Q) homomeric kainate receptor using 
both FLIPR/Ca2+ inﬂux and electrophysiological methods. 
UoS12258 did not potentiate NMDA receptor, GluN1/2B-mediated activity at any concentration 
tested whether tested by Ca2+ inﬂux or whole-cell patch clamp. Similarly, in FLIPR experiments on 
transiently expressed kainite receptors, UoS12258 did not show any activity either as an agonist, an-
tagonist or positive modulator. Identical results were obtained using electrophysiological analysis. 
UoS12258 also produced no signiﬁcant potentiation in activity at rat NMDA or kainate receptors 
suggesting that this compound exhibits selectivity for AMPA compared to other glutamate receptor 
subtypes. 
Cognition 
UoS12258 improved performance in three different cognition paradigms using a variety of 
approaches to cause impairments (i.e. delay, scopolamine and age). 
The NOR test was the most sensitive paradigm, particularly following sub-chronic dosing. UoS12258 
reversed a delay-induced deﬁcitin NOR in rats after both acute dosing and sub-chronic dosing. 
However, behavioural studies in the water maze showed that although UoS12258 was effective at 
improving aged-induced deﬁcits in learning and retention, the MED, 3 mg·kg฀1, was higher than in 
the NOR study. This difference could be a reﬂection of young and aged rats’ performance in 
particular cognitive tasks, or it could be due to the underlying mechanisms involved in performing 
the task. NOR is dependent on the innate curiosity of the rat to explore novelty and might be more 
sensitive to modulation of AMPA receptor activity than in a model that involves the complex 
physiological processes, which are altered during cognitive impairment associated with ageing. 
Similarly the higher MED (3 mg·kg฀1) in the passive avoidance cognition model could reﬂect the 
increased difﬁculty in overcoming a scopolamine-induced impairment compared to a time-induced 
deﬁcit used in the NOR model. 
Interestingly, a bell-shaped dose–response relationship (i.e. loss of, or reduced, effect at higher 
doses) was apparent in both the NOR and water maze paradigms. 
In addition to UoS12258 being an AMPA receptor positive modulator, microdialysis studies have 
shown that it also enhances cholinergic neurotransmission in brain structures, the dorsal 
hippocampus and anterior cingulate cortex, which are implicated in cognitive functioning. 
Safety and tolerability 
Although UoS12258 decreased seizure threshold at doses greater than 10 mg·kg฀1, it should be 
noted that brain concentrations in the MEST test were approximately 20-fold higher than 
concentrations measured after improved performance of NOR after acute dosing. Further research is 
ongoing to identify molecules that exhibit a greater margin between efﬁcacious exposures and those 
which evoke proconvulsant activity. 
Conclusions 
UoS12258 is a selective positive allosteric modulator of AMPA-type ionotropic glutamate receptors 
exhibiting equivalent potency at all AMPA receptor subtypes, with no measurable activity on other 
glutamate receptors. At comparable concentrations (10–15 nM), UoS12258 has been shown to 
potentiate AMPA receptor-mediated currents in vitro;enhance synaptic AMPA receptor-mediated 
activity in vivo as well as demonstrating an excellent in vivo efﬁcacy proﬁle. UoS12258 improved 
NOR task performance in the rat at low brain concentrations, which were consistent with its activity 
on native tissue in vitro; importantly, efﬁcacious concentrations were signiﬁcantly lower than those 
required for efﬁcacy with compounds such as CX516 in a similar assay (Damgaard et al., 2010). 
UoS12258 was also effective at improving rats’ performance of water maze and passive avoidance 
suggestive of enhanced learning and memory, although at higher concentrations. On the basis of the 
preclinical studies reported in this article, UoS12258 would be expected to be highly efﬁcacious at 
improving cognitive measures in schizophrenic patients as well as other diseases with cognitive 
impairments, and is therefore a worthy candidate for clinical evaluation. 
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Table S1 Mean ± sem pEC50 values for 1 potentiation of AMPA receptors formed from homomeric 
combination of different GluA subunits. 
Table S2 Summary pEC50 values for 1 on speciﬁc AMPA mediate current parameters in rat 
hippocampal neurones. Table S3 Blood and brain concentrations of 1 after performance of NOR task 
(dosed 4 h prior to T1 and T2, n =3). Table S4 Blood and brain concentrations of 1 following 
performance of NOR task. Rats were dosed daily for 7 days and then 4hpriortoT1andT2(n =3). 
Table S5 (1.0, 3.0, 10 mg/kg, p.o., 4 h ptt) in LH rats in the proconvulsant MEST test. Signiﬁcant 
differences (* P < 0.05 or ***P < 0.001) compared to vehicle treated animals. 
